Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 1/20 | 0.39 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.39 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | SAT1 | P21673 | 1/20 | 0.37 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | NCF1 | P14598 | 1/20 | 0.33 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19098396 | 0.90 | CYP2C9 (0.35) | GNAI3GNAO1GNAI1SAT1NCF1 | |
| SCHEMBL19098395 | 0.84 | GNAI3 (0.42) | GNAI3GNAO1GNAI1SAT1NCF1 | |
| SCHEMBL19098712 | 0.83 | GNAI3 (0.43) | GNAI3GNAO1GNAI1TDP1SAT1 | |
| SCHEMBL19083193 | 0.81 | TDP1 (0.35) | GNAI3GNAO1GNAI1TDP1SAT1 | |
| SCHEMBL19098392 | 0.80 | NCF1 (0.39) | GNAI3GNAO1GNAI1SAT1NCF1 | |
| SCHEMBL10864747 | 0.79 | GNAI3 (0.50) | GNAI3GNAO1GNAI1TDP1SAT1 | |
| SCHEMBL8036569 | 0.75 | SIGMAR1 (0.53) | GNAI3GNAO1GNAI1TDP1SAT1 | |
| SCHEMBL19098394 | 0.75 | NCF1 (0.38) | GNAI3GNAO1GNAI1SAT1NCF1 | |
| SCHEMBL20159608 | 0.75 | KEAP1 (0.53) | PAOXLMNAKDM4E | |
| SCHEMBL9478831 | 0.75 | LMNA (0.48) | GNAI3GNAO1GNAI1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017120164-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | Tabomedex Biosciences, LLC (US) | 2017-07-13 | — | — | WO | disclosed |
| US-20170190713-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | WUXI APPTEC (HONG KONG) CO., LIMITED (HK) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190713-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | MKNK2, CYP2J2, PTGS2 | GNAI3 261/4885GNAO1 1468/4885GNAI1 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.